Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741722 | 1.00 | CYP2D6 (0.40) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL4071150 | 0.86 | CYP2D6 (0.37) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL19919497 | 0.74 | — | — | |
| SCHEMBL2028987 | 0.70 | HRH3 (0.32) | — | |
| SCHEMBL2028983 | 0.70 | HRH3 (0.32) | — | |
| SCHEMBL2031312 | 0.70 | HRH3 (0.32) | — | |
| SCHEMBL2702821 | 0.67 | — | — | |
| SCHEMBL23421119 | 0.62 | CYP2C19 (0.71) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL13973941 | 0.62 | CYP2C19 (0.71) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL22362543 | 0.62 | ALOX15 (0.53) | CYP2D6LMNABLMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4251615-B1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024215870-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POLYMERASE THETA AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Redona Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| CN-117777132-A | alpha-N-arylamino amide and preparation method and medicinal application thereof | 江苏豪森药业集团有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116457352-A | Aryloxazolo spiro derivatives for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-8283363-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LABORATORIES (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-8236798-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-08-07 | — | — | US | disclosed |
| CN-102482212-A | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO KG | 2012-05-30 | — | — | CN | disclosed |
| WO-2011058122-A1 | PIPERIDINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118314-A1 | PIPERIDINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | YUN WEIYA | 2011-05-19 | — | — | US | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CYP2D6 2751/4885LMNA 1711/4885BLM 4869/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CYP2D6 2751/4885LMNA 1711/4885BLM 4869/4885 |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | CYP2D6 77/4885LMNA 1803/4885BLM 776/4885 |
| US-20110118314-A1 | PIPERIDINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | CYP2D6 1440/4885LMNA 810/4885BLM 3197/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | CYP2D6 3877/4885LMNA 1674/4885BLM 1347/4885 |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | NSUN3, NSUN2, RBM3 | CYP2D6 4510/4885LMNA 1072/4885BLM 1279/4885 |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | CYP2D6 35/4885LMNA 1265/4885BLM 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.